On October 17, Lexaria Bioscience Corp Got Nasdaq Bid Price Deficiency Notice
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience Corp received a Nasdaq Bid Price Deficiency Notice on October 17, according to an SEC filing.
October 18, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lexaria Bioscience Corp received a Nasdaq Bid Price Deficiency Notice, which could potentially lead to delisting if not rectified.
Receiving a Nasdaq Bid Price Deficiency Notice means that the company's stock has not met the minimum bid price requirement set by Nasdaq for continued listing. If the company fails to meet this requirement within the specified timeframe, it could face delisting. This news is likely to negatively impact investor sentiment and could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100